Organon (OGN) said Wednesday it has agreed to acquire Roivant's (ROIV) Dermavant, including its flagship dermatological cream Vtama, for a total consideration of $1.2 billion.
Under the deal, Organon will pay $175 million upfront with $75 million as milestone payment after the US Food and Drug Administration approves Vtama's application for treatment of atopic dermatitis, followed by commercial milestone payments of up to $950 million. The companies expect the FDA to decide on its review in Q4.
The transaction is expected to close in Q4.
Price: 20.22, Change: -0.33, Percent Change: -1.61
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。